Skip to main content
padlock icon - secure page this page is secure

Immunomodulation, Part I: Pentoxifylline

Buy Article:

$17.00 + tax (Refund Policy)

SEPSIS CONTINUES TO BE A significant cause of neonatal morbidity and mortality. In a recent study by the National Institute of Child Health and Human Development Neonatal Research Network, 21 percent of very low birth weight neonates older than three days of age had one or more episodes of proven bloodstream sepsis (range for the 15 network centers: 11–32 percent). The study's authors assert that strategies to decrease the incidence of nosocomial infection and the related social and economic impact are urgently needed.1 Researchers have been exploring various modalities, including immunomodulation, as adjuncts to antibiotics to enhance the neonatal immune system. Generally, immunomodulators act to stimulate or augment the immune system indirectly.

No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: July 1, 2005

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more